What Happened
- The United States and India announced a landmark interim bilateral trade deal in February 2026, the first substantive trade agreement between the two countries in decades.
- The US agreed to lower its "reciprocal tariff" on Indian goods from 25% to 18%, removing an additional 25% tariff linked to India's commitment to halt purchases of Russian Federation oil.
- India agreed to eliminate or reduce tariffs across a wide range of US goods, address non-tariff barriers in priority sectors (medical devices, ICT), and commit to purchasing $500 billion of U.S. energy, aircraft, technology, and coking coal products over five years.
- The deal covers a defined product basket from both sides; agriculture and dairy are largely excluded from the tariff concessions, remaining politically sensitive red lines for India.
- This editorial piece analysed whether the deal represents a genuine resolution of trade tensions or a managed accommodation with structural issues unresolved.
Static Topic Bridges
Structure of the U.S.-India Interim Trade Agreement
The February 2026 agreement is technically a "Phase 1" interim framework pending a broader Bilateral Trade Agreement (BTA) negotiation. It represents the culmination of trade talks launched during PM Modi's February 2025 Washington visit. The US applied what it called "IEEPA-based reciprocal tariffs" — invoking the International Emergency Economic Powers Act — to a range of trading partners, including India, arguing that asymmetric tariff structures constituted an economic emergency. The interim deal resolves some but not all tariff asymmetries.
- US tariff on India: reduced from 25% to 18% on a defined product basket including textiles, leather, chemicals, gems, pharmaceuticals, aircraft parts.
- Additional 25% tariff linked to Russian oil purchases: removed after India committed to cease Russian oil imports.
- India's commitments: tariff elimination on US goods, NTB resolution (medical devices, ICT), and purchase commitments.
- $500 billion US product purchase commitment over 5 years: covers energy, aircraft, precious metals, technology, coking coal.
- Generic pharmaceuticals, gems and diamonds, and aircraft parts: US reciprocal tariff removed entirely.
Connection to this news: The editorial context is the tension between the deal's framing as "historic" and the significant unresolved issues — particularly agriculture, the full scope of tariff reductions, and the absence of a formal legal text — which leave the durability of the agreement in question.
IEEPA Tariffs — Legal and Trade Policy Context
The International Emergency Economic Powers Act (IEEPA) is a US statute that grants the President broad authority to regulate commerce with foreign countries in response to declared national emergencies. The Trump administration invoked IEEPA in 2025 to impose tariffs on multiple trading partners, arguing that trade deficits constituted a national security emergency. This was a legally novel use of IEEPA for tariff purposes — previously it had been used for sanctions and asset freezes rather than broad import duties. The WTO rules generally prohibit arbitrary tariff increases above bound rates, but IEEPA tariffs are imposed through executive order rather than WTO-consistent safeguard mechanisms.
- IEEPA enacted: 1977; grants the US President emergency economic powers to deal with unusual and extraordinary threats.
- WTO bound rates for India on US goods: vary by sector but generally 3–10% for manufactures.
- India's WTO-compliant tariff response: India filed a WTO dispute against IEEPA tariffs, joined by the EU and Canada.
- Pre-deal US tariff on India: 25% (IEEPA-based) + additional sector tariffs; post-deal: 18% baseline.
- The deal's legal form: not a formal FTA ratified by the US Congress, but an executive-level framework — potentially reversible by a future administration.
Connection to this news: The editorial's "end in sight" framing is complicated by the deal's executive (not legislative) nature — a future US administration could unilaterally walk back the tariff reductions without congressional action, making long-term planning difficult for Indian exporters.
India-US Bilateral Trade — Size, Composition, and Deficit
The United States is India's largest bilateral trading partner, with total merchandise trade of approximately $130–140 billion per year. The bilateral trade balance has historically favoured India — India runs a trade surplus with the US — which has been a persistent irritant in the relationship. India exports gems and jewellery, pharmaceuticals, software services (not captured in merchandise data), textiles, organic chemicals, and engineering goods to the US. India imports from the US: aircraft, machinery, crude oil, coal, fertilisers, electronic components, and medical devices.
- Total India-US merchandise trade: approximately $130–140 billion in 2024-25.
- India's merchandise trade surplus with US: approximately $35–45 billion annually.
- Services trade: India exports approximately $50 billion in software/IT services to the US annually; US exports financial and educational services.
- Top Indian exports to US: gems and jewellery (~$9B), pharma (~$8B), textiles (~$6B), engineering goods (~$5B).
- Top US exports to India: aircraft, petroleum products, coal, fertilisers, machinery.
Connection to this news: The trade deal was directly motivated by the US desire to reduce its merchandise deficit with India. Understanding the composition of bilateral trade is essential to assessing which sectors gain or lose from the deal's specific tariff concessions.
Non-Tariff Barriers (NTBs) as a Persistent Trade Friction
Non-tariff barriers — regulatory, procedural, and technical obstacles to trade — are often more impactful than tariff differentials for high-value goods like medical devices, ICT products, and agricultural commodities. US trade negotiators have long flagged India's price capping of medical devices (orthopaedic implants, cardiac stents), mandatory BIS certification requirements for ICT goods, data localisation policies, and import licensing requirements as significant NTBs. India agreed under the 2026 interim deal to address these in specific priority areas.
- Medical devices: India's National Pharmaceutical Pricing Authority (NPPA) has imposed price caps on cardiac stents (₹27,890 since 2017) and knee implants — major US export categories.
- ICT goods: India's BIS (Bureau of Indian Standards) mandatory testing requirements have been flagged as duplicative of international safety standards.
- India agreed to "determine within 6 months whether US-developed or international standards are acceptable" for US ICT exports.
- Data localisation: Reserve Bank of India's mandate that payment data be stored domestically has affected US fintech companies operating in India.
- NTB resolution is harder to verify and enforce than tariff cuts — a key reason why "Phase 1" deals often fall short of transformative impact.
Connection to this news: The editorial's sceptical tone about whether there is truly an "end in sight" reflects the difficulty of verifying NTB concessions — unlike a tariff number, NTB removal involves regulatory changes across multiple ministries and agencies.
Key Facts & Data
- US tariff on India: reduced from 25% to 18% under the interim deal (February 2026).
- Additional 25% tariff on Indian goods linked to Russian oil purchases: removed.
- India's $500 billion purchase commitment from the US over 5 years: energy, aircraft, tech, coking coal.
- Total India-US merchandise trade: ~$130–140 billion annually; India runs a ~$35–45 billion surplus.
- Agriculture and dairy: largely excluded from both sides' tariff concessions.
- IEEPA (1977): US statute invoked to impose tariffs via executive order; not WTO-consistent safeguard mechanism.
- Deal structure: Phase 1 executive framework; broader BTA negotiations ongoing.
- India top US exports: gems and jewellery, pharmaceuticals, textiles, organic chemicals, engineering goods.
- Top US exports to India: aircraft, petroleum products, coal, fertilisers, machinery.